Categories: News

Yield10 Bioscience to Present at the H.C. Wainwright 25th Annual Global Investment Conference

WOBURN, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11-13, 2023, at the Lotte New York Palace Hotel.

President and Chief Executive Officer Oliver Peoples, Ph.D. will present a corporate overview that will also include a business update. The presentation will be available on demand on September 11, 2023 beginning at 7:00am ET. Dr. Peoples will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.

A live webcast of the presentation and a replay will be available on the Investor Relations section of the Company’s website at IR Events & Presentations | Yield10 Bioscience, Inc.

About Yield10 Bioscience

Yield10 Bioscience, Inc. is an agricultural bioscience company that is using its differentiated trait gene discovery platform, the “Trait Factory”, to develop improved Camelina varieties for the production of proprietary seed products, and to discover high value genetic traits for the agriculture and food industries. Our goals are to efficiently establish a high value seed products business based on developing superior varieties of Camelina for the production of feedstock oils for renewable diesel, PHA bioplastics and omega-3 (EPA, DHA+EPA) oils, and to license our yield traits to major seed companies for commercialization in major row crops, including corn, soybean and canola. Yield10 is headquartered in Woburn, MA and has a Canadian subsidiary, Yield10 Oilseeds Inc., located in Saskatoon, Canada.

For more information about the company, please visit www.yield10bio.com, or follow the Company on X (formerly Twitter)Facebook and LinkedIn.

(YTEN-G)

Contacts:

Yield10 Bioscience:
Lynne H. Brum, (617) 682-4693, LBrum@yield10bio.com

Investor Relations:
Bret Shapiro, (561) 479-8566, brets@coreir.com
Managing Director, CORE IR

Media Inquiries:
Eric Fischgrund, eric@fischtankpr.com
FischTank PR

Staff

Recent Posts

Analysis Finds Misinformation About Interchangeable Biosimilars Undermining US Health Policy, Physician Confidence, and Patient Health

WASHINGTON, DC / ACCESSWIRE / July 16, 2024 / The Alliance for Safe Biologic Medicines…

2 hours ago

Vituity Cares Foundation Joins Forces With the Magic Johnson Foundation and Justin Carr Wants World Peace Foundation for the 2nd Annual Back-to-School Community Event in LA

Comprehensive Back-to-School Event on Saturday, July 20, 2024, Will Feature Life-Saving Cardiac Screenings Alongside Free…

2 hours ago

Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery, Upcoming Webinar Hosted by HitGen and Xtalks

CHENGDU, China, July 16, 2024 /PRNewswire/ -- "Evolving DNA-Encoded Library Technology and Its Application for Innovative…

5 hours ago

AI Tool Successfully Responds to Patient Questions in Electronic Health Record

NEW YORK, July 16, 2024 /PRNewswire/ -- As part of a nationwide trend, many more…

5 hours ago

TeleSpecialists Revolutionizes Stroke Care with Launch of Innovative EMS Integration Service

EMS Integration to enhance door-to-needle times and elevate patient outcomes FORT MYERS, Fla., July 16,…

5 hours ago

XO Health Powers Provider Search and Improved Transparency with Kyruus Health

BOSTON, July 16, 2024 /PRNewswire/ -- XO Health, an innovative health care services organization designed…

5 hours ago